NHS England and NICE have approved the use of Tirzepatide, which you may also know as Mounjaro® or ‘the weight loss drug’, from primary care. You may well hear that Tirzepatide is available from primary care from 23rd June 2025. However, in the first two years entry criteria have been set by NHS England to a very small number of people. This is to allow safe entry of this repurposed medicine into the health system.
Please only contact us if you are eligible, this means you have a BMI of 40 or higher and at least four of these additional conditions, which will already have been diagnosed by your GP or another medical professional:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Type 2 diabetes mellitus